Enfortumab vedotin and pembrolizumab combination shows a 49% reduction in mortality risk for advanced bladder cancer compared to chemotherapy. ASCO GU symposium focuses on antibody-drug conjugates, ...
Pfizer and Astellas Pharma said a treatment for certain bladder-cancer patients demonstrated positive topline results in a Phase 3 study. In the trial, the combination of Padcev with Merck & Co.'s ...
AstraZeneca (NASDAQ:AZN) has announced positive results from a late-stage trial testing Imfinzi (durvalumab) combined with Bacillus Calmette-Guérin (BCG) therapy as a bladder cancer treatment. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback